Your browser is no longer supported. Please, upgrade your browser.
Aerovate Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand23.11M Perf Week-29.67%
Market Cap424.04M Forward P/E- EPS next Y-1.13 Insider Trans- Shs Float4.20M Perf Month-33.29%
Income- PEG- EPS next Q-0.26 Inst Own83.30% Short Float26.52% Perf Quarter-3.94%
Sales- P/S- EPS this Y-193.20% Inst Trans1.44% Short Ratio9.58 Perf Half Y-
Book/sh-0.93 P/B- EPS next Y26.10% ROA- Target Price24.67 Perf Year-
Cash/sh1.97 P/C7.16 EPS next 5Y- ROE- 52W Range11.40 - 29.43 Perf YTD-38.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-51.99% Beta-
Dividend %- Quick Ratio14.10 Sales past 5Y- Gross Margin- 52W Low23.95% ATR2.30
Employees8 Current Ratio14.10 Sales Q/Q- Oper. Margin- RSI (14)38.63 Volatility13.56% 13.16%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.91 Prev Close17.37
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume116.26K Price14.13
Recom1.50 SMA20-23.70% SMA50-16.98% SMA200-14.14% Volume106,261 Change-18.65%
Jul-26-21Initiated Wedbush Outperform $23
Jul-26-21Initiated Jefferies Buy $21
Jul-26-21Initiated Evercore ISI Outperform $30
Jul-26-21Initiated Cowen Outperform
Sep-30-21 06:40AM  
Sep-21-21 05:05AM  
Sep-17-21 08:00AM  
Aug-16-21 08:00AM  
Jul-19-21 08:00AM  
Jul-02-21 04:01PM  
Jun-29-21 10:59PM  
Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.